Oliver Lagore Vanvalin Investment Group Vaxcyte, Inc. Transaction History
Oliver Lagore Vanvalin Investment Group
- $359 Million
- Q3 2024
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 80 shares of PCVX stock, worth $5,972. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80
Previous 121
33.88%
Holding current value
$5,972
Previous $9,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$893 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$790 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$742 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$649 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$464 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.43B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...